Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
Daiichi, Merck pull HER3-DXd filing at FDA
After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in consecutive years.
Eric Sagonowsky
May 29, 2025 9:40am
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
Daiichi taps Nosis to deliver RNA therapies beyond the liver
Mar 11, 2025 10:24am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
Daiichi gins up antibody research collab with German institute
Jan 14, 2025 3:44pm
